Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction
Key facts
- Who runs it
- Kowa Research Institute, Inc.
- Where
- Beverly Hills, Gainesville, Grand Junction, Houston, Hurst, Lynchburg, Mt. Pleasant, and St Louis, United StatesSee the 9 sites
- Trial code
- Status
- Recruiting
- People taking part
- 340 people, planned
- Started
- 30 Oct 2026
- Expected to end
- Sept 2028
- Type of study
- Interventional
- Treatments tested
- KI-362-US1 (YP2.2VM)
- Record updated
- 13 November 2026
Who can take part
- Age
- 22 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Are able and willing to provide written informed consent, attend all scheduled visits, and comply with all trial procedures and follow-up
- Have a study eye with visually significant cataract for which phacoemulsification cataract extraction and posterior chamber IOL implantation is indicated
- Meet all other inclusion criteria outlined in the clinical study protocol
Who cannot take part
- Within 30 days of the Screening Visit, use of systemic medications with significant ocular side effects or any medications that could confound the outcome or increase participant risk
- Have serious systemic disease that could increase operative risk or conditions that can confound the surgical outcome
- Meet any other exclusion criteria outlined in the clinical study protocol
Where in United States
- Beverly Hills Institute of OphthalmologyBeverly Hills, United StatesContact: Director, Clinical OperationsTaking people
- North Georgia Eye AssociatesGainesville, United StatesContact: Director, Clinical OperationsTaking people
- Icon EyeCareGrand Junction, United StatesContact: Director, Clinical OperationsTaking people
- Berkeley EyeHouston, United StatesContact: Director, Clinical OperationsTaking people
- Houston Eye Associates, North LoopHouston, United StatesContact: Director, Clinical OperationsTaking people
- Texas Eye ResearchHurst, United StatesContact: Director, Clinical OperationsTaking people
- Piedmont Eye CenterLynchburg, United StatesContact: Director, Clinical OperationsTaking people
- Carolina Eyecare PhysiciansMt. Pleasant, United StatesContact: Director, Clinical OperationsTaking people
- Ophthalmology Consultants LtdSt Louis, United StatesContact: Director, Clinical OperationsTaking people
About the trial
What the trial wants to find out
This study is designed to evaluate how well an artificial lens, called an intraocular lens (IOL), performs in adults undergoing cataract surgery. During cataract surgery, the eye's natural lens is removed and replaced with an artificial lens to improve vision.
Read full original descriptionShow less
The main goal of the study is to evaluate participants' vision after the IOL is placed in the eye. Approximately one year after surgery, participants' vision will be assessed to determine how clearly they can see.
The results of this study will provide additional information about the performance of the IOL in adults undergoing cataract surgery.
The group in the trial
- KI-362-US1Treatment being tested
Participants receive an intraocular lens (IOL) implanted during cataract surgery to replace the natural lens of the eye. The IOL is delivered using a single-use, preloaded delivery device and positioned within the eye's natural lens capsule.
Treatment: KI-362-US1 (YP2.2VM)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter, Open-label, Single-arm Clinical Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) IOL for Correction of Aphakia Following Cataract Extraction
- Record updated
- 13 November 2026